psychedelics

News

Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.

R&D

The next phase of psychiatry must go toward treatments that are not only novel, but practical, personalised, and accessible.

News

Armed with new data, Compass wants to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression.

News

Helus' psychedelic derived from ayahuasca, a brew used in shamanistic rituals in South America, has shown promise as a treatment for depression.

News

A $390m merger of two pioneers of psychedelic medicines has completed to create AtaiBeckley, with a pipeline of candidates for mental illnesses.

News

UK psychiatrists have called for a relaxation of restrictive rules on testing psychedelics, which are holding back research and clinical use.